1222 related articles for article (PubMed ID: 30852032)
1. New horizons in bladder cancer research.
Boormans JL; Zwarthoff EC; Black PC; Goebell PJ; Kamat AM; Nawroth R; Seiler R; Williams SB; Schmitz-Dräger BJ
Urol Oncol; 2020 Dec; 38(12):867-885. PubMed ID: 30852032
[TBL] [Abstract][Full Text] [Related]
2. Macromolecular crowding: chemistry and physics meet biology (Ascona, Switzerland, 10-14 June 2012).
Foffi G; Pastore A; Piazza F; Temussi PA
Phys Biol; 2013 Aug; 10(4):040301. PubMed ID: 23912807
[TBL] [Abstract][Full Text] [Related]
3. From the History of the Croatian Dermatovenereological Society - The Croatian Medical Association and an Overview of Important Information Regarding the Journal Acta Dermatovenerologica Croatica.
Dobrić I
Acta Dermatovenerol Croat; 2018 Dec; 26(4):344-348. PubMed ID: 30665489
[TBL] [Abstract][Full Text] [Related]
4. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer.
Kamoun A; de Reyniès A; Allory Y; Sjödahl G; Robertson AG; Seiler R; Hoadley KA; Groeneveld CS; Al-Ahmadie H; Choi W; Castro MAA; Fontugne J; Eriksson P; Mo Q; Kardos J; Zlotta A; Hartmann A; Dinney CP; Bellmunt J; Powles T; Malats N; Chan KS; Kim WY; McConkey DJ; Black PC; Dyrskjøt L; Höglund M; Lerner SP; Real FX; Radvanyi F;
Eur Urol; 2020 Apr; 77(4):420-433. PubMed ID: 31563503
[TBL] [Abstract][Full Text] [Related]
5. 25 years International Bladder Cancer Network (IBCN): The past, the present, and the future.
Dyrskjøt L; Vlahou A; Black PC; Droller M; Grossmann HB; Goebell PJ; Kamat AM; Nawroth R; Seiler R; Todenhöfer T; Williams SB; Schmitz-Dräger BJ
Urol Oncol; 2023 Jul; 41(7):302-306. PubMed ID: 36437158
[TBL] [Abstract][Full Text] [Related]
6. Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer.
Necchi A; Raggi D; Gallina A; Ross JS; Farè E; Giannatempo P; Marandino L; Colecchia M; Lucianò R; Bianchi M; Colombo R; Salonia A; Gandaglia G; Fossati N; Bandini M; Pederzoli F; Capitanio U; Montorsi F; de Jong JJ; Dittamore R; Liu Y; Davicioni E; Boormans JL; Briganti A; Black PC; Gibb EA
Eur Urol; 2020 Jun; 77(6):701-710. PubMed ID: 32165065
[TBL] [Abstract][Full Text] [Related]
7. Alignment of molecular subtypes across multiple bladder cancer subtyping classifiers.
Reike MJ; de Jong JJ; Bismar TA; Boorjian SA; Mian OY; Wright JL; Dall'Era MA; Kaimakliotis HZ; Lotan Y; Boormans JL; Black PC; Gibb EA
Urol Oncol; 2024 Jun; 42(6):177.e5-177.e14. PubMed ID: 38480079
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the tumor-infiltrating immune repertoire in muscle invasive bladder cancer.
Benítez R; Yu K; Sirota M; Malats N; Pineda S
Front Immunol; 2023; 14():986598. PubMed ID: 36817478
[TBL] [Abstract][Full Text] [Related]
9. The inaugural Qatar Critical Care Conference with its Qatar Medical Journal Special Issue - An important milestone.
Hassan IF; Alinier G
Qatar Med J; 2019; 2019(2):1. PubMed ID: 31763204
[TBL] [Abstract][Full Text] [Related]
10. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
[TBL] [Abstract][Full Text] [Related]
11. Abass Alavi: A giant in Nuclear Medicine turns 80 and is still going strong!
Høilund-Carlsen PF
Hell J Nucl Med; 2018; 21(1):85-87. PubMed ID: 29550853
[TBL] [Abstract][Full Text] [Related]
12. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.
Efstathiou JA; Mouw KW; Gibb EA; Liu Y; Wu CL; Drumm MR; da Costa JB; du Plessis M; Wang NQ; Davicioni E; Feng FY; Seiler R; Black PC; Shipley WU; Miyamoto DT
Eur Urol; 2019 Jul; 76(1):59-68. PubMed ID: 30712971
[TBL] [Abstract][Full Text] [Related]
13. The evolution of bladder cancer genomics: What have we learned and how can we use it?
Audenet F; Attalla K; Sfakianos JP
Urol Oncol; 2018 Jul; 36(7):313-320. PubMed ID: 29573965
[TBL] [Abstract][Full Text] [Related]
14. The NCI All Ireland Cancer Conference.
Johnston PG; Daly PA; Liu E
Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
[TBL] [Abstract][Full Text] [Related]
15. A quantitative polymerase chain reaction based method for molecular subtype classification of urinary bladder cancer-Stromal gene expressions show higher prognostic values than intrinsic tumor genes.
Olah C; Hahnen C; Nagy N; Musial J; Varadi M; Nyiro G; Gyorffy B; Hadaschik B; Rawitzer J; Ting S; Sjödahl G; Hoffmann MJ; Reis H; Szarvas T
Int J Cancer; 2022 Mar; 150(5):856-867. PubMed ID: 34536301
[TBL] [Abstract][Full Text] [Related]
16. Identification and validation of poor prognosis immunoevasive subtype of muscle-invasive bladder cancer with tumor-infiltrating podoplanin
Zhou Q; Wang Z; Zeng H; Zhang H; Liu Z; Huang Q; Wang J; Chang Y; Bai Q; Liu L; Zhu Y; Xu L; Dai B; Guo J; Xia Y; Wang Y; Xu J
Oncoimmunology; 2020 Apr; 9(1):1747333. PubMed ID: 33457092
[TBL] [Abstract][Full Text] [Related]
17. SIU-ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer.
Leow JJ; Bedke J; Chamie K; Collins JW; Daneshmand S; Grivas P; Heidenreich A; Messing EM; Royce TJ; Sankin AI; Schoenberg MP; Shipley WU; Villers A; Efstathiou JA; Bellmunt J; Stenzl A
World J Urol; 2019 Jan; 37(1):61-83. PubMed ID: 30684034
[TBL] [Abstract][Full Text] [Related]
18. Proceedings of the Second Workshop on Theory meets Industry (Erwin-Schrödinger-Institute (ESI), Vienna, Austria, 12-14 June 2007).
Hafner J
J Phys Condens Matter; 2008 Feb; 20(6):060301. PubMed ID: 21693862
[TBL] [Abstract][Full Text] [Related]
19. An International Collaborative Consensus Statement on En Bloc Resection of Bladder Tumour Incorporating Two Systematic Reviews, a Two-round Delphi Survey, and a Consensus Meeting.
Teoh JY; MacLennan S; Chan VW; Miki J; Lee HY; Chiong E; Lee LS; Wei Y; Yuan Y; Yu CP; Chow WK; Poon DM; Chan R; Lai F; Ng CF; Breda A; Kramer MW; Malavaud B; Mostafid H; Herrmann T; Babjuk M
Eur Urol; 2020 Oct; 78(4):546-569. PubMed ID: 32389447
[TBL] [Abstract][Full Text] [Related]
20. Fibronectin-1: A Predictive Immunotherapy Response Biomarker for Muscle‑Invasive Bladder Cancer.
Zhang X; Liu H; Zhang J; Wang Z; Yang S; Liu D; Liu J; Li Y; Fu X; Zhang X
Arch Esp Urol; 2023 Feb; 76(1):70-83. PubMed ID: 36914422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
